ADH1 and ADH2 Disease Monitoring Study (DMS)

Active, not recruitingOBSERVATIONAL
Enrollment

95

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

November 30, 2028

Study Completion Date

December 31, 2028

Conditions
Autosomal Dominant Hypocalcemia
Trial Locations (27)

2065

Royal North Shore Hospital, Saint Leonards

3000

Universitaire Ziekenhuizen Leuven, Leuven

8200

Aarhus University Hospital, Aarhus

20122

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan

20132

IRCCS Ospedale San Raffaele, Milan

27834

Physician's East Endocrinology, Greenville

32207

Nemours Children's Clinic, Jacksonville

37075

Endokrinologikum Gottingen, Göttingen

43210

Ohio State University Medical Center (OSUMC), Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Indiana University (IU) School of Medicine - University Hospital, Indianapolis

55902

Mayo Clinic, Rochester

59000

CHU de Lille, Lille

69003

HCL Hopital Edouard Herriot, Lyon

69500

HCL Hopital Femme Mere Enfant, Bron

80045

Children's Hospital Colorado, Aurora

94270

Departement d'Endocrinologie et Diabetes pour Enfants - AP-HP Hopital Bicetre, Le Kremlin-Bicêtre

94609

University of California, San Francisco (UCSF) - Benioff Children's Hospital - Oakland, Oakland

02115

Boston Children's Hospital, Boston

L6M 1M1

Bone Research and Education Centre, Oakville

00290

Helsinki University Hospital (HUS) - The New Children's Hospital, Helsinki

00128

Policlinico Universitario Campus Bio-Medico, Rome

565-0871

Osaka University Hospital, Osaka

113-8655

The University of Tokyo Hospital, Tokyo

3015 GD

Erasmus MC, Rotterdam

1649-028

Centro Hospitalar Universitario de Lisboa Norte - Hospital de Santa Maria, Lisbon

M13 9WL

Royal Manchester Children's Hospital, Manchester

All Listed Sponsors
lead

Calcilytix Therapeutics, Inc., a BridgeBio company

INDUSTRY

NCT05227287 - ADH1 and ADH2 Disease Monitoring Study (DMS) | Biotech Hunter | Biotech Hunter